Allogene Therapeutics (ALLO) acknowledged the passing of founding board member, David Bonderman. “We are deeply saddened by the passing of our founding board member and dear friend,” said Arie Belldegrun, M.D., Executive Chairman. “David was more than a board member – he was a champion of innovation, a trusted mentor, and an enduring source of inspiration to all of us. He was also an unwavering believer in the groundbreaking potential of CAR T therapy. Long before Allogene was founded, David recognized the promise of this innovative approach, becoming one of the earliest advocates and supporters of Kite Pharma. His passion and dedication only deepened over time as he helped to guide the establishment and evolution of Allogene. Words cannot express how much he will be missed.”
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALLO:
- JPMorgan healthcare analysts hold an analyst/industry conference call
- Biotech Alert: Searches spiking for these stocks today
- Allogene Therapeutics presents data for ALLO-329 in autoimmune disease
- Allogene Therapeutics price target lowered to $9 from $11 at Piper Sandler
- Allogene Therapeutics Advances CAR T Therapies
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
